Cargando…

Correction: Pitavastatin and Atorvastatin Double-Blind Randomized ComPArative Study among HiGh-Risk Patients, Including ThOse with Type 2 Diabetes Mellitus, in Taiwan (PAPAGO-T Study)

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236170/ http://dx.doi.org/10.1371/journal.pone.0114175

Ejemplares similares

Pitavastatin and Atorvastatin Double-Blind Randomized ComPArative Study among HiGh-Risk Patients, Including ThOse with Type 2 Diabetes Mellitus, in Taiwan (PAPAGO-T Study)
por: Liu, Ping-Yen, et al.
Publicado: (2013)

papago indians at work
por: Waddell, Jack O., 1933-
Publicado: (1969)

Biografía de una mujer pápago
por: Underhill, Ruth, 1883-1984
Publicado: (1975)

Biografía de una mujer pápago
por: Underhill, Ruth, 1883-1984
Publicado: (1975)

Metil paratión : efectos sobre la salud y el ambiente. Documento provisional
por: Papa, Lynn
Publicado: (1987)

Weltweites Grid zur Urknallforschung fast parat
Publicado: (2006)

Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats
por: Koladiya, Rajeshkumar U, et al.
Publicado: (2008)

Parat: index of acronyms and abbreviations in electrical and electronic engineering
por: Büro Scientia. Berlin
Publicado: (1989)

Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia
por: Mita, Tomoya, et al.
Publicado: (2013)

Pitavastatin versus Atorvastatin: Potential Differences in their Effects on Serum Lipoprotein Lipase and Cardiovascular Disease
por: Kobayashi, Junji
Publicado: (2022)

Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study
por: Liu, Wei-Ting, et al.
Publicado: (2020)

Determinación de paratión (p-Nitrofeniltiofosfato de 0,0-etil). : /
por: Hernández Hernández, Daniel
Publicado: (2008)

α-d-Tagatopyranose
por: Punzo, Francesco, et al.
Publicado: (2009)

The OSE complotype and its clinical potential
por: Alic, Lejla, et al.
Publicado: (2022)

Pleiotropic effects of pitavastatin
por: Davignon, Jean
Publicado: (2012)

Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study
por: Lin, Liang-Yu, et al.
Publicado: (2014)

A sePARate phase? Poly(ADP-ribose) versus RNA in the organization of biomolecular condensates
por: Alemasova, Elizaveta E, et al.
Publicado: (2022)

Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial
por: Tsujita, Kenichi, et al.
Publicado: (2023)

Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases
por: Seo, Won-Woo, et al.
Publicado: (2022)

Interaction of the pitavastatin with model membranes
por: Shurshalova, Guzel S., et al.
Publicado: (2021)

β-catenin/Tcf-signaling appears to establish the murine ovarian surface epithelium (OSE) and remains active in selected postnatal OSE cells
por: Usongo, Macalister, et al.
Publicado: (2012)

Efficacy and Safety of Pitavastatin in a Real-World Setting: Observational Study Evaluating SaFety in Patient Treated with Pitavastatin in Korea (PROOF Study)
por: Jeong, In-Kyung, et al.
Publicado: (2020)

6-Deoxy-α-l-talopyranose
por: Booth, K. Victoria, et al.
Publicado: (2008)

A first-principles study on the phonon transport in layered BiCuOSe
por: Shao, Hezhu, et al.
Publicado: (2016)

Atorvastatin Use Associated With Acute Pancreatitis: A Case-Control Study in Taiwan
por: Lai, Shih-Wei, et al.
Publicado: (2016)

Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial
por: Park, Jun-Bean, et al.
Publicado: (2017)

Pitavastatin in cardiometabolic disease: therapeutic profile
por: Masana, Luis
Publicado: (2013)

2-Deoxy-α-d-arabino-hexopyranose
por: Hess, David, et al.
Publicado: (2011)

Unmet therapeutic, educational and scientific needs in parathyroid disorders: Consensus Statement from the first European Society of Endocrinology Workshop (PARAT)
por: Bollerslev, Jens, et al.
Publicado: (2019)

Pitavastatin: evidence for its place in treatment of hypercholesterolemia
por: Alagona, Peter
Publicado: (2010)

Effect of Pitavastatin on Vascular Reactivity in Hypercholesterolemic Rabbits
por: de Almeida, Eros Antonio, et al.
Publicado: (2014)

Magnon spectrum of the helimagnetic insulator Cu(2)OSeO(3)
por: Portnichenko, P. Y., et al.
Publicado: (2016)

Italian Validation of the Online Student Engagement Scale (OSE) in Higher Education
por: Sulla, Francesco, et al.
Publicado: (2023)

Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia
por: Sasaki, Jun
Publicado: (2010)

Statins in cardiometabolic disease: what makes pitavastatin different?
por: Ginsberg, Henry
Publicado: (2013)

Pitavastatin suppressed liver cancer cells in vitro and in vivo
por: You, He-Yi, et al.
Publicado: (2016)

Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, in vitro and in vivo
por: Cho, Yongin, et al.
Publicado: (2020)

Pitavastatin Is a Highly Potent Inhibitor of T-Cell Proliferation
por: Voss, Linda, et al.
Publicado: (2021)

Parent artery reconstruction for large or giant cerebral aneurysms using a Tubridge flow diverter (PARAT): study protocol for a multicenter, randomized, controlled clinical trial
por: Zhou, Yu, et al.
Publicado: (2014)

2,3-O-Isopropylidene-3-C-phenylerythrofuranose
por: Robinson, Tony V., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_9kc2c58k4oa4cgg25j26581h71